Finanzen von Nektar Therapeutics (NKTR)NKTRNektar Therapeutics

Evaluating the bottom line, Nektar Therapeutics maintains a gross margin of 100.00%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at -412.23%, while the net margin is -400.97%. These profitability ratios, combined with a Return on Equity (ROE) of -35.75%, provide a clear picture of how effectively NKTR converts its operational activities into shareholder value.

In the context of the broader market, NKTR competes directly with industry leaders such as LBRX and GHRS. With a market capitalization of $1.30B, it holds a significant position in the sector. When comparing efficiency, NKTR's gross margin of 100.00% stands against LBRX's N/A and GHRS's N/A. Such benchmarking helps identify whether Nektar Therapeutics is trading at a premium or discount relative to its financial performance.

Nektar has reported significant losses, with a net income of -40.62 million USD in Q2 2026 and a gross margin of 100% in recent quarters, indicating potential for high profitability if revenues stabilize.